Sera Prognostics inks deal with MultiPlan for pregnancy test

LabPulse.com staff writers
Jan 31, 2022
2022 02 01 23 05 7997 Business Contract Signing 400

Sera Prognostics has signed an agreement with MultiPlan to add its PreTRM pregnancy biomarker blood test to MultiPlan's private healthcare system (PHCS) and MultiPlan Networks.

As a result of the deal, more than 700 healthcare payers and 1.2 million healthcare providers participating in MultiPlan's provider networks will be able to order PreTRM Test, a proteomic blood test for measuring a woman's risk of spontaneous preterm birth.
Latest in Agreement
Hands Shaking Deal Social
Codexis, Alphazyme forge licensing agreement for genomics enzymes
October 3, 2024
Business Agreement Social
Scancell, PharmaJet sign agreement for melanoma vaccine delivery system
September 18, 2024
Body composition in patients treated with Ozempic
Sponsored
Body composition in patients treated with Ozempic
September 20, 2024
Bladder Urinary 3 D Social
A. Menarini, Nucleix sign distribution agreement for bladder cancer test
September 9, 2024
Related Stories
Blood Test Samples Lab Social
Collaboration
Blood test could improve detection of potentially fatal pregnancy complication: study
Hospital Baby Nurse Social
Preterm Birth
Fors Marsh to offer Sera Prognostics preterm birth risk test to employees
Teething Baby Doctor Social
Collaboration
Biora Therapeutics, Avero Diagnostics to develop preeclampsia rule-out test
Body composition in patients treated with Ozempic
Sponsor Content
Body composition in patients treated with Ozempic
More in Agreement
Codexis, Alphazyme forge licensing agreement for genomics enzymes
By LabPulse.com staff writers
Enzyme engineering firm Codexis has entered into a commercial and manufacturing license agreement with Alphazyme for multiple enzymes from Codexis' life science enzyme portfolio.
October 3, 2024
Hands Shaking Deal Social
Scancell, PharmaJet sign agreement for melanoma vaccine delivery system
By LabPulse.com staff writers
Clinical-stage biopharmaceutical company Scancell has signed a strategic partnership agreement with PharmaJet for the supply of PharmaJet's needle-free Stratis delivery system for the delivery of Scancell's advanced melanoma vaccine.
September 18, 2024
Business Agreement Social
CDC adds commercial lab contracts for infectious disease, bird flu testing
By Liz Carey
Clinical laboratories incentivized to develop diagnostic tests earlier.
September 17, 2024
Colorized transmission electron micrograph of avian influenza A H5N1 virus particles shown in yellow.
A. Menarini, Nucleix sign distribution agreement for bladder cancer test
By LabPulse.com staff writers
A. Menarini Diagnostics and liquid biopsy firm Nucleix have signed a strategic partnership for the exclusive distribution of Nucleix's Bladder EpiCheck test.
September 9, 2024
Bladder Urinary 3 D Social
Carolina Liquid Chemistries, Medline sign distribution deal for POC fentanyl screening test
By LabPulse.com staff writers
Carolina Liquid Chemistries has forged an agreement with medical supply manufacturer and distributor Medline Industries to distribute its point-of-care fentanyl screening test kit to healthcare providers and clinical laboratories across the U.S.
August 2, 2024
Alcohol Drugs Pills Social
Siga Technologies, HHS sign $113M procurement deal for smallpox, mpox treatment
By LabPulse.com staff writers
Biotech company Siga Technologies announced that the U.S. Department of Health and Human Services (HHS) exercised a procurement option on an existing contract with Siga to deliver approximately $113 million of the firm's oral antiviral treatment TPoxx.
July 22, 2024
3 D Monkeypox Infecting Cell Social
Patient Square Capital to acquire NanoString assets for $220M
By LabPulse.com staff writers
NanoString Technologies has reached a binding agreement with Patient Square Capital in which NanoString will sell substantially all of its assets to the investment firm for $220 million.
March 11, 2024
Business Agreement Social
Flatiron Health, Guardant Health to integrate tests, EMR platform
By LabPulse.com staff writers
Flatiron Health and Guardant Health have signed an agreement to integrate Guardant’s genomic profiling test portfolio into Flatiron’s cloud-based OncoEMR electronic medical record (EMR) platform.
November 1, 2023
Business Agreement Social
Astellas snags chance to license Poseida cell therapy in $50M deal
By Nick Paul Taylor
The agreement gives Astellas first refusal for partnering on P-MUC1C-ALLO1, an allogeneic chimeric antigen receptor (CAR) T cell therapy product candidate that Poseida is developing as a treatment for solid tumors.
August 9, 2023
T Cell Social
Guardant and Illumina resolve lawsuit, reach agreement
By Nick Paul Taylor
In a statement, Guardant said the “three-year agreement includes a joint request to dismiss with prejudice the pending litigation between the companies.” The request to dismiss includes “any allegations related to the subject intellectual property.”
August 7, 2023
Business Men Handshake Social
Siemens Healthineers to distribute Scopio Labs’ full-field digital cell morphology technology
By LabPulse.com staff writers
Siemens Healthineers said the Scopio X100 and Scopio X100HT imaging platforms will complement its IVD systems, including the Atellica Hema 570 and Atellica Hema 580 analyzers.
May 8, 2023
Nanoparticle Blood Social
Werfen signs distribution agreement with Thermo Fisher for hemostasis diagnostics system
By LabPulse.com staff writers
The exclusive, long-term agreement allows Barcelona-based Werfen to continue offering the HemoCell Specialized Lab Automation system.
May 4, 2023
Business Agreement Social
Page 1 of 17
Next Page